This is an early operational update with no efficacy data. Monitor for Part C completion and topline safety/efficacy readouts, which are the next catalysts. The $3M market cap implies high binary risk — any positive data could be material, but failure risk is equally high.
Price Chart
Executive Summary
Clearmind Medicine announced the initiation of Phase IIa of its Phase I/IIa trial for CMND-100 in Alcohol Use Disorder, with six patients enrolled (one-third of Part C). The trial advanced following a positive DSMB review of Part A safety data. This is an early-stage operational milestone for a pre-revenue biotech with a $3M market cap, providing no financial data or efficacy results.
Key Facts
- Phase IIa of CMND-100 for Alcohol Use Disorder has been initiated with six patients enrolled.
- Three patients enrolled at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center.
- The DSMB reviewed Part A data and recommended advancing to subsequent study parts.
- CMND-100 is a non-hallucinogenic psychedelic-derived neuroplastogen candidate.
- Clearmind holds 19 patent families including 32 granted patents.
Financial Impact
No financial data reported; pre-revenue clinical-stage company with $3M market cap.
Risk Factors
- No efficacy data reported; Phase IIa is early-stage with high failure risk for psychedelic-based AUD treatments.
- Micro-cap ($3M) with limited cash runway; dilution risk from prior F-3 shelf registrations is present.
- Enrollment of only 6 patients provides no statistical power for efficacy conclusions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-095981 |
| Document: ea030419902ex99-1.htm | 0001213900-26-095981 |
| Document: 0001213900-26-095981-index-headers.html | 0001213900-26-095981 |
| Document: 0001213900-26-095981-index.html | 0001213900-26-095981 |
| Document: 0001213900-26-095981.txt | 0001213900-26-095981 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.74%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.45%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.31%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers